文献速递心力衰竭与心肌病

口服松弛素受体激动剂 AZD5462 治疗慢性心衰的 LUMINARA 试验主要结果

Oral Relaxin Receptor Agonist AZD5462 in Participants With Chronic Heart Failure: Primary Results From the LUMINARA Trial.
PubMed 文献 · Circulation · 2026-08-30

LUMINARA 试验纳入左心室射血分数≤35%或41%–55%的慢性心衰患者,随机接受 AZD5462 20、80、360 mg 每日一次或安慰剂治疗 24 周。结果显示 AZD5462 耐受性良好,在射血分数 41%–55% 组中所有剂量均显著降低全身血管阻力指数,在射血分数≤35% 组中 20 mg 组降低收缩末期容积指数的安慰剂校正变化为 -5.4 mL/m²。

要点

  • AZD5462 每日一次口服在慢性心衰患者中耐受性良好。
  • 射血分数 41%–55% 组所有剂量均显著降低全身血管阻力指数。
  • 射血分数≤35% 组 20 mg 组收缩末期容积指数有下降趋势。

核心结论

  • 在已接受良好指南指导药物治疗的慢性心衰患者中,加用口服 AZD5462 耐受性良好,并在宽泛的左心室射血分数范围内显示出对心血管血流动力学指标的有益作用。
  • 需要更大规模和更长随访时间的试验来评估 AZD5462 对心衰临床结局的影响。

研究设计与样本

  • 国际、多中心、双盲、安慰剂对照、剂量探索试验,在 10 个国家 57 个中心开展。
  • 纳入左心室射血分数≤35%(队列 A)或 41%–55%(队列 B)的慢性心衰成人患者,按 1:1:1:1 随机分配至 AZD5462 20、80、360 mg 或安慰剂每日一次口服。
  • 队列 A 共随机 235 例,平均年龄 65 岁,88% 为男性;队列 B 共随机 140 例,平均年龄 70 岁,69% 为男性。
  • 主要终点为 24 周后收缩末期容积指数(队列 A)和全身血管阻力指数(队列 B)的变化。

主要发现

  • 队列 A 中,第 25 周时 AZD5462 20 mg 组的收缩末期容积指数较基线的安慰剂校正变化为 -5.4 mL/m²(95% CI,-10.9 至 0.1;P=0.054)。
  • 队列 B 中,第 25 周时 AZD5462 所有剂量组的全身血管阻力指数均出现显著的安慰剂校正降低(所有 P <0.05)。
  • 与安慰剂相比,AZD5462 治疗耐受性良好。
  • 入组患者基线时接受的指南指导心衰药物治疗情况良好。

关键数值与推荐

  • 队列 A 纳入标准为左心室射血分数≤35%。
  • 队列 B 纳入标准为左心室射血分数 41%–55%。
  • 试验干预剂量为 AZD5462 20、80、360 mg 每日一次口服。
  • 主要终点评估时间点为 24 周后的第 25 周。

临床怎么用

  • 在慢性心衰患者中,口服 AZD5462 可能作为改善血流动力学的潜在治疗选择,需等待更大规模结局试验验证。

局限性

  • 本试验为剂量探索设计,样本量有限,未评估临床结局。
  • 随访时间较短,仅观察 24 周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stimulation of the relaxin family peptide receptor 1 experimentally reduces systemic vascular resistance and afterload, improves organ perfusion, and fosters reverse cardiac remodeling. We hypothesized that AZD5462, an oral once-daily relaxin family peptide receptor 1 agonist, may benefit individuals with chronic heart failure (HF). METHODS: In this international, multicenter, double-blind, placebo-controlled, dose-ranging trial, adults with chronic HF and left ventricular ejection fraction ≤35% (cohort A) or 41% to 55% (cohort B) were randomized 1:1:1:1 to 3 (20, 80, or 360 mg) once-daily oral doses of AZD5462 or placebo. Primary end points were changes in end-systolic volume index (cohort A) and systemic vascular resistance index (cohort B) after 24 weeks. RESULTS: A total of 235 (cohort A) and 140 (cohort B) participants were randomized across 57 sites in 10 countries. The mean age was 65 and 70 years, and 88% and 69% were male; baseline concomitant guideline-directed medical therapy for HF was excellent. Treatment with AZD5462 was well tolerated compared with placebo. In cohort A, at week 25, treatment with AZD5462 20 mg showed a placebo-adjusted end-systolic volume index change from baseline of -5.4 mL/m2 (95% CI, -10.9 to 0.1; P=0.054). In cohort B, AZD5462 treatment resulted in significant placebo-adjusted reductions in systemic vascular resistance index at week 25 across all dose groups (all P <0.05). CONCLUSIONS: Among individuals with well-treated chronic HF, the addition of oral AZD5462 was well tolerated and demonstrated encouraging effects on cardiovascular hemodynamic measures across a wide range of left ventricular ejection fraction. Larger and longer duration trials are warranted to assess the impact of AZD5462 on clinical outcomes in HF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06299826.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Januzzi, Rosenmeier, Ely Pizzato, et al. Oral Relaxin Receptor Agonist AZD5462 in Participants With Chronic Heart Failure: Primary Results From the LUMINARA Trial. Circulation. 2026. PMID: 42668430. doi:10.1161/CIRCULATIONAHA.126.082763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。